Ding Congyi, Jia Qiyu, Wu Zhongjie, Zhang Yanfei, Hu Yi, Wang Jingyu, Wei Dahai
Jiaxing University Master Degree Cultivation Base, Zhejiang Chinese Medical University, Jiaxing, Zhejiang, China.
Department of Trauma Orthopedics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Front Oncol. 2023 Aug 31;13:1186991. doi: 10.3389/fonc.2023.1186991. eCollection 2023.
This study aimed to investigate and analyze the clinical application value of thoracoscopic segmentectomy and lobectomy in patients with invasive pulmonary adenocarcinoma.
286 patients with invasive pulmonary adenocarcinoma who underwent segmentectomy or lobectomy at the First Hospital of Jiaxing City from January 2018 to June 2020 were retrospectively analyzed. Patients were divided into a thoracoscopic segmentectomy group(n=97) and a lobectomy group (n=189). Patients were compared after obtaining 1:1 propensity score-matched cohorts. Outcome indicators included surgery-related indicators, immune-inflammation-related indicators, postoperative complications, recurrence, and metastasis.
After 1:1 propensity score matching, 93 patients were included in each group. We found that the volume of intraoperative blood loss in the segmentectomy group was significantly less than in the lobectomy group (P=0.014). The duration of postoperative drainage (P = 0.005) and hospitalization (P=0.002) in the segmentectomy group were significantly shorter than in the lobectomy group. In terms of immunoinflammatory response, compared with the lobectomy group, white blood cells, neutrophils, SII, and NLR in the segmentectomy group were significantly lower than in the lobectomy group (P< 0.05). The recurrence-free survival (RFS) rates in the segmentectomy and lobectomy were 80.5% and 88.2% at 1 year and 35.1% and 52.6% at 3 years, respectively, and the difference was statistically significant (P<0.05). The segmentectomy group achieved similar outcomes to the lobectomy group at 1 year and 3 years (P > 0.05). Multivariate COX regression analysis showed that CAR was an independent risk factor for RFS in patients undergoing invasive adenocarcinoma surgery.
Compared with lobectomy, thoracoscopic segmentectomy can effectively reduce the postoperative inflammatory response in patients with early invasive lung adenocarcinoma and promote patient recovery. Although segmentectomy is associated with a higher recurrence rate in the short term for patients with early invasive lung adenocarcinoma, the associated survival rate is similar to the lobectomy group. Segmentectomy should be considered in the treatment of early invasive lung adenocarcinoma. Meanwhile, postoperative CAR represents an independent risk factor for early postoperative recurrence in patients with IAC.
本研究旨在探讨和分析胸腔镜肺段切除术与肺叶切除术在浸润性肺腺癌患者中的临床应用价值。
回顾性分析2018年1月至2020年6月在嘉兴市第一医院接受肺段切除术或肺叶切除术的286例浸润性肺腺癌患者。患者分为胸腔镜肺段切除术组(n = 97)和肺叶切除术组(n = 189)。在获得1:1倾向评分匹配队列后对患者进行比较。观察指标包括手术相关指标、免疫炎症相关指标、术后并发症、复发和转移情况。
经过1:1倾向评分匹配后,每组纳入93例患者。我们发现肺段切除术组术中出血量显著少于肺叶切除术组(P = 0.014)。肺段切除术组术后引流时间(P = 0.005)和住院时间(P = 0.002)均显著短于肺叶切除术组。在免疫炎症反应方面,与肺叶切除术组相比,肺段切除术组的白细胞、中性粒细胞、SII和NLR均显著低于肺叶切除术组(P < 0.05)。肺段切除术组和肺叶切除术组1年无复发生存率(RFS)分别为80.5%和88.2%,3年分别为35.1%和52.6%,差异有统计学意义(P < 0.05)。肺段切除术组在1年和3年时取得了与肺叶切除术组相似的结果(P > 0.05)。多因素COX回归分析显示,CAR是浸润性腺癌手术患者RFS的独立危险因素。
与肺叶切除术相比,胸腔镜肺段切除术可有效减轻早期浸润性肺腺癌患者术后的炎症反应,促进患者恢复。虽然对于早期浸润性肺腺癌患者,肺段切除术短期内复发率较高,但其生存率与肺叶切除术组相似。在早期浸润性肺腺癌的治疗中应考虑肺段切除术。同时,术后CAR是IAC患者术后早期复发的独立危险因素。